Volume 3 Issue 2

From the Desk of Editor-in-Chief…

Pharma industries in India has made significant positive impact to health care outcomes across the globe. However, the scenario has changed when India government signed the TRIPS agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights), that came in to effect on Jan 1, 2005 which resulted in protection of product patents. Generic medicines (products produced by manufacturer other than the innovator company after the original patent has expired. A generic drug is a medication created to be the same as an already marketed brand-name drug in a dosage form, strength, route of administration, quality, performance characteristics, and intended use. In other words, their pharmacological effects (safety and efficacy) are equivalent to the innovator’s drug. From cost reduction point of view, generic prescriptions have played very important role in health care, saving billions of dollars to drug buyers and consumers. “Pradhan Mantri Jan Ausodhi” in India has played a magic contribution in providing drugs with quality and efficacy at a very low price. There is significant growth in pharma sector in last five decades since 1970’s Indian Patent Act to TRIPS Agreement. With in this five decades focus has increased for generic drugs and API market focus, more focus on export of drugs growth in Research and development, vigilant on intellectual property laws, development in Novel Drug Delivery, artificial intelligences, biosimilars, CROs for services, collaborative research. Biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from innovators biologic product. The biosimilars research has the potential to change the commercial landscape of traditional pharma companies as profoundly as generics research has done in the past. A symbiotic growth in Academia and Industry can further improve the scope and vision in pharma sector across the globe. I wish Happy Teachers Day, to all the teachers that is to be celebrated on 5th of September. Let’s celebrate and enjoy the 75th Azadi Ka Amrut Mohotsav by all Indians.


Anjan Kumar Mahapatra
Editor-in-Chief, RJPLS

Published Articles:-
SL NO.Book NameAuthor Name'sPage No.
1Key Considerations in Biomedical Research EthicsY Roja Ramani[01-02]
2Potential of Herbal Drugs for Application against Alzheimer’s disease Pragyan Parimita Mansingh, Lopamudra Adhikari, Shakti Ketan Prusty [03-32]
3Study of Regulatory Requirements for Registration of Pharmaceutical Products in Africa MarketP. Sunil Prusty, Pramila Chauhan, Ajit Nahak[33-48]
4Regulatory guidance on Forced degradation studies- A review Tulasi Pradhan, Susanta Kumar Panda[49-71]
5Simultaneous Determination of Albendazole and Praziquantel Using Zero Order Spectrophotometry Absorbance correction Methods in Veterinary Pharmaceutical FormulationSuddhasattya Dey, Robina Khatun, Rajiv Jash, Shreya Shah, Pankaj Dagur, Padmacharan Behera, Sourav Khawas and Anirban Nandi[72-90]
6Development and Validation of a UV-Vis Spectrophotometric Method for Determination of Pitavastatin in Bulk and Its Dosage FormSaroj Kanta Bisoyi, Sudhir Kumar Sahoo, Saroj Kumar Panda[91- 99]
7Adverse Drug Reactions of Commonly Used Antifungal Drugs A Pharmacovigilance StudyAmitder Nath Chatterjee, Barsha Giri, Debjit Kar[100-105]
8Formulation and Evaluation of Fexofenadine HCl Fast Dissolving TabletsMalaya Kumar Dalai, Shakti Prasad Samantasinghara, Rashmiranjan Nayak, Meenakshi Behera, Ritanjali Ghadei[106-115]